Younger women with breast cancer who had a mastectomy demonstrated a worse quality of life (QoL) compared with those who underwent breast-conserving surgery (BCS), according to a study presented at SABCS 2018.
Use of a scalp cooling device is effective in reducing alopecia or hair loss in patients with breast cancer who are undergoing neoadjuvant/adjuvant chemotherapy including anthracyclines* and taxanes**, according to studies presented at SABCS 2018.
Women diagnosed with nonmetastatic breast cancer who were adherent to cardiovascular disease (CVD) medications pre-diagnosis had a high risk of becoming nonadherent post-cancer treatment, with nonadherence increasing their risk of CV events, according to a poster presented at the recent San Antonio Breast Cancer Symposium (SABCS 2018).
A lifestyle intervention programme focusing on healthy habits was associated with weight loss and better disease-free survival (DFS) among early breast cancer survivors, according to the SUCCESS C* study presented at SABCS 2018.
The anticholinergic agent oxybutynin significantly reduces the intensity and frequency of hot flushes among women in whom hormone replacement therapy was contraindicated such as breast cancer survivors, according to the ACCRU study SC-1603 presented at SABCS 2018.
A structured cardiovascular (CV) exercise programme during adjuvant breast cancer treatment provides significant protection against decline in CV function related to chemotherapy-induced cardiotoxicity, according to the EBBA*-II trial presented at SABCS 2018, indicating that physical activity during treatment for breast cancer can benefit patients.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.